The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
ATR/CHK1 inhibitors and cancer therapy
Open accessAbstract
The cell cycle checkpoint proteins ataxia-telangiectasia-mutated-and-Rad3-related kinase (ATR) and its major downstream effector checkpoint kinase 1 (CHK1) prevent the entry of cells with damaged or incompletely replicated DNA into mitosis when the cells are challenged by DNA damaging agents, such as radiation therapy (RT) or chemotherapeutic drugs, that are the major modalities to treat cancer. This regulation is particularly evident in cells with a defective G1 checkpoint, a common feature of cancer cells, due to p53 mutations. In addition, ATR and/or CHK1 suppress replication stress (RS) by inhibiting excess origin firing, particularly in cells with activated oncogenes. Those functions of ATR/CHK1 make them ideal therapeutic targets. ATR/CHK1 inhibitors have been developed and are currently used either as single agents or paired with radiotherapy or a variety of genotoxic chemotherapies in preclinical and clinical studies. Here, we review the status of the development of ATR and CHK1 inhibitors. We also discuss the potential mechanisms by which ATR and CHK1 inhibition induces cell killing in the presence or absence of exogenous DNA damaging agents, such as RT and chemotherapeutic agents. Lastly, we discuss synthetic lethality interactions between the inhibition of ATR/CHK1 and defects in other DNA damage response (DDR) pathways/genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sensing DNA Damage Through ATRIP Recognition of RPA-ssDNA Complexes
Zou, L., & Elledge, S. J. (2003) · Science · doi:10.1126/science.1083430 · Cited by 2,693
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
Causes and consequences of replication stress
Zeman, M. K., & Cimprich, K. A. (2014) · Nature Cell Biology · doi:10.1038/ncb2897 · Cited by 2,079
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
XRCC3 promotes homology-directed repair of DNA damage in mammalian cells
Pierce, A. J., Johnson, R. D., Thompson, L. H., & Jasin, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2633 · Cited by 1,379
Peng, C.-Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., & Piwnica-Worms, H. (1997) · Science · doi:10.1126/science.277.5331.1501 · Cited by 1,341
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,276
Endogenous DNA damage in humans: a review of quantitative data
De Bont, R. (2004) · Mutagenesis · doi:10.1093/mutage/geh025 · Cited by 1,058
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
ATR and ATRIP: Partners in Checkpoint Signaling
Cortez, D., Guntuku, S., Qin, J., & Elledge, S. J. (2001) · Science · doi:10.1126/science.1065521 · Cited by 985
ATR disruption leads to chromosomal fragmentation and early embryonic lethality
Brown, E. J., & Baltimore, D. (2000) · Genes & Development · doi:10.1101/gad.14.4.397 · Cited by 951
ATR prohibits replication catastrophe by preventing global exhaustion of RPA
Toledo, L. I., Altmeyer, M., Rask, M.-B., Lukas, C., Larsen, D. H., Povlsen, L. K., Bekker-Jensen, S., Mailand, N., Bartek, J., & Lukas, J. (2013) · Cell · doi:10.1016/j.cell.2013.10.043 · Cited by 911
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair
Sørensen, C. S., Hansen, L. T., Dziegielewski, J., Syljuåsen, R. G., Lundin, C., Bartek, J., & Helleday, T. (2005) · Nature Cell Biology · doi:10.1038/ncb1212 · Cited by 666
ATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 635
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J.-D., MacCormick, S., Charlton, P. A., Golec, J. M. C., & Pollard, J. R. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.573 · Cited by 633
Sørensen, C. S., Syljuåsen, R. G., Falck, J., Schroeder, T., Rönnstrand, L., Khanna, K. K., Zhou, B.-B., Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00048-5 · Cited by 559
Syljuåsen, R. G., Sørensen, C. S., Hansen, L. T., Fugger, K., Lundin, C., Johansson, F., Helleday, T., Sehested, M., Lukas, J., & Bartek, J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.9.3553-3562.2005 · Cited by 550
Graves, P. R., Yu, L., Schwarz, J. K., Gales, J., Sausville, E. A., O'Connor, P. M., & Piwnica-Worms, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5600 · Cited by 544
Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465
CHK2 kinase in the DNA damage response and beyond
Zannini, L., Delia, D., & Buscemi, G. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju045 · Cited by 455 · cited 1×
“However, they cannot compensate for the loss of each other [19,20].”
BackgroundRegulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle.
Watanabe, N., Broome, M., & Hunter, T. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07180.x · Cited by 450
Cell Cycle Regulation of DNA Replication
Sclafani, R. A., & Holzen, T. M. (2007) · Annual Review of Genetics · doi:10.1146/annurev.genet.41.110306.130308 · Cited by 450
Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice
de Klein, A., Muijtjens, M., van Os, R., Verhoeven, Y., Smit, B., Carr, A. M., Lehmann, A. R., & Hoeijmakers, J. H. J. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00447-4 · Cited by 443
New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
Dai, Y., & Grant, S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1029 · Cited by 439
Sister Chromatid Exchanges Are Mediated by Homologous Recombination in Vertebrate Cells
Sonoda, E., Sasaki, M. S., Morrison, C., Yamaguchi-Iwai, Y., Takata, M., & Takeda, S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.7.5166 · Cited by 426
Zabludoff, S. D., Deng, C., Grondine, M. R., Sheehy, A. M., Ashwell, S., Caleb, B. L., Green, S., Haye, H. R., Horn, C. L., Janetka, J. W., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0492 · Cited by 413
Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation
O'Connell, M. J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.3.545 · Cited by 398
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
Murga, M., Campaner, S., Lopez-Contreras, A. J., Toledo, L. I., Soria, R., Montaña, M. F., D'Artista, L., Schleker, T., Guerra, C., Garcia, E., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2189 · Cited by 381
Fokas, E., Prevo, R., Pollard, J. R., Reaper, P. M., Charlton, P. A., Cornelissen, B., Vallis, K. A., Hammond, E. M., Olcina, M. M., Gillies McKenna, W., et al. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.181 · Cited by 369
Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells
Bindra, R. S., Schaffer, P. J., Meng, A., Woo, J., Måseide, K., Roth, M. E., Lizardi, P., Hedley, D. W., Bristow, R. G., & Glazer, P. M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8504-8518.2004 · Cited by 356
A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging
Murga, M., Bunting, S., Montaña, M. F., Soria, R., Mulero, F., Cañamero, M., Lee, Y., McKinnon, P. J., Nussenzweig, A., & Fernandez-Capetillo, O. (2009) · Nature Genetics · doi:10.1038/ng.420 · Cited by 340
Chan, N., Koritzinsky, M., Zhao, H., Bindra, R., Glazer, P. M., Powell, S., Belmaaza, A., Wouters, B., & Bristow, R. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5472 · Cited by 328
Hypoxia Links ATR and p53 through Replication Arrest
Hammond, E. M., Denko, N. C., Dorie, M. J., Abraham, R. T., & Giaccia, A. J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.6.1834-1843.2002 · Cited by 324
Activation of mammalian Chk1 during DNA replication arrest
Feijoo, C., Hall-Jackson, C., Wu, R., Jenkins, D., Leitch, J., Gilbert, D. M., & Smythe, C. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200104099 · Cited by 318
Buisson, R., Boisvert, J. L., Benes, C. H., & Zou, L. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.029 · Cited by 316
Chk1 promotes replication fork progression by controlling replication initiation
Petermann, E., Woodcock, M., & Helleday, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005031107 · Cited by 308
Beck, H., Nähse-Kumpf, V., Larsen, M. S. Y., O'Hanlon, K. A., Patzke, S., Holmberg, C., Mejlvang, J., Groth, A., Nielsen, O., Syljuåsen, R. G., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00412-12 · Cited by 306
Morgan, M. A., Parsels, L. A., Zhao, L., Parsels, J. D., Davis, M. A., Hassan, M. C., Arumugarajah, S., Hylander-Gans, L., Morosini, D., Simeone, D. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3573 · Cited by 303
ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks
Lavin, M. F. (2007) · Oncogene · doi:10.1038/sj.onc.1210880 · Cited by 301
Deregulation of cyclin E in human cells interferes with prereplication complex assembly
Ekholm-Reed, S., Méndez, J., Tedesco, D., Zetterberg, A., Stillman, B., & Reed, S. I. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200404092 · Cited by 296
Jones, R. M., Mortusewicz, O., Afzal, I., Lorvellec, M., García, P., Helleday, T., & Petermann, E. (2013) · Oncogene · doi:10.1038/onc.2012.387 · Cited by 295
Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
Sausville, E. A., Arbuck, S. G., Messmann, R., Headlee, D., Bauer, K. S., Lush, R. M., Murgo, A., Figg, W. D., Lahusen, T., Jaken, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2319 · Cited by 291
Positive Regulation of Wee1 by Chk1 and 14-3-3 Proteins
Lee, J., Kumagai, A., & Dunphy, W. G. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.3.551 · Cited by 291
Kwok, M., Davies, N., Agathanggelou, A., Smith, E., Oldreive, C., Petermann, E., Stewart, G., Brown, J., Lau, A., Pratt, G., et al. (2016) · Blood · doi:10.1182/blood-2015-05-644872 · Cited by 276
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
Ma, C. X., Janetka, J. W., & Piwnica-Worms, H. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.009 · Cited by 271
Hirose, Y., Berger, M. S., & Pieper, R. O. (2001) · PubMed · Cited by 262
Charrier, J.-D., Durrant, S. J., Golec, J. M. C., Kay, D. P., Knegtel, R. M. A., MacCormick, S., Mortimore, M., O'Donnell, M. E., Pinder, J. L., Reaper, P. M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101488z · Cited by 255
Cole, K. A., Huggins, J., Laquaglia, M., Hulderman, C. E., Russell, M. R., Bosse, K., Diskin, S. J., Attiyeh, E. F., Sennett, R., Norris, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012351108 · Cited by 249
Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
Chan, N., Pires, I. M., Bencokova, Z., Coackley, C., Luoto, K. R., Bhogal, N., Lakshman, M., Gottipati, P., Oliver, F. J., Helleday, T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2352 · Cited by 244
Prevo, R., Fokas, E., Reaper, P. M., Charlton, P. A., Pollard, J. R., McKenna, W. G., Muschel, R. J., & Brunner, T. B. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21093 · Cited by 241
Vendetti, F. P., Lau, A., Schamus, S., Conrads, T. P., O’Connor, M. J., & Bakkenist, C. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6247 · Cited by 239
(1997) · PubMed · Cited by 238
Targeting the ATR-CHK1 Axis in Cancer Therapy
Rundle, S., Bradbury, A., Drew, Y., & Curtin, N. (2017) · Cancers · doi:10.3390/cancers9050041 · Cited by 231
Jackson, J. R., Gilmartin, A. G., Imburgia, C. S., Winkler, J. D., Marshall, L. A., & Roshak, A. (2000) · PubMed · Cited by 229
Gilad, O., Nabet, B. Y., Ragland, R. L., Schoppy, D. W., Smith, K. D., Durham, A. C., & Brown, E. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2286 · Cited by 228
Ma, C. X., Cai, S., Li, S., Ryan, C. E., Guo, Z., Schaiff, W. T., Lin, L., Hoog, J., Goiffon, R. J., Prat, A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58765 · Cited by 225
Preventing replication fork collapse to maintain genome integrity
Cortez, D. (2015) · DNA Repair · doi:10.1016/j.dnarep.2015.04.026 · Cited by 223
Blasina, A., Hallin, J., Chen, E., Arango, M. E., Kraynov, E., Register, J., Grant, S., Ninkovic, S., Chen, P., Nichols, T., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2391 · Cited by 223
(1996) · PubMed · Cited by 221
Liu, Q., Wang, J., Kang, S. A., Thoreen, C. C., Hur, W., Ahmed, T., Sabatini, D. M., & Gray, N. S. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101520v · Cited by 219
Foote, K. M., Blades, K., Cronin, A., Fillery, S., Guichard, S. S., Hassall, L., Hickson, I., Jacq, X., Jewsbury, P. J., McGuire, T. M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301859s · Cited by 214
Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis
Busino, L., Chiesa, M., Draetta, G. F., & Donzelli, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207394 · Cited by 211
ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status
Huntoon, C. J., Flatten, K. S., Wahner Hendrickson, A. E., Huehls, A. M., Sutor, S. L., Kaufmann, S. H., & Karnitz, L. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0110 · Cited by 202
Fuse, E., Tanii, H., Kurata, N., Kobayashi, H., Shimada, Y., Tamura, T., Sasaki, Y., Tanigawara, Y., Lush, R. D., Headlee, D. J., et al. (1998) · PubMed · Cited by 200
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B., Gu, Y., Hare, B., Johnson, M. A., Li, H., Milton, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2158 · Cited by 199
Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease
Domínguez-Kelly, R., Martín, Y., Koundrioukoff, S., Tanenbaum, M. E., Smits, V. A. J., Medema, R. H., Debatisse, M., & Freire, R. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201101047 · Cited by 196
Peasland, A., Wang, L.-Z., Rowling, E., Kyle, S., Chen, T., Hopkins, A., Cliby, W. A., Sarkaria, J., Beale, G., Edmondson, R. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.243 · Cited by 195
Sausville, E., LoRusso, P., Carducci, M., Carter, J., Quinn, M. F., Malburg, L., Azad, N., Cosgrove, D., Knight, R., Barker, P., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2380-5 · Cited by 192
Targeting ATR in DNA damage response and cancer therapeutics
Fokas, E., Prevo, R., Hammond, E. M., Brunner, T. B., McKenna, W. G., & Muschel, R. J. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.03.002 · Cited by 189
LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
King, C., Diaz, H. B., McNeely, S., Barnard, D., Dempsey, J., Blosser, W., Beckmann, R., Barda, D., & Marshall, M. S. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1037 · Cited by 187
Daud, A. I., Ashworth, M. T., Strosberg, J., Goldman, J. W., Mendelson, D., Springett, G., Venook, A. P., Loechner, S., Rosen, L. S., Shanahan, F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.5027 · Cited by 185
Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR
Schoppy, D. W., Ragland, R. L., Gilad, O., Shastri, N., Peters, A. A., Murga, M., Fernandez-Capetillo, O., Diehl, J. A., & Brown, E. J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58928 · Cited by 182
Petermann, E., Maya-Mendoza, A., Zachos, G., Gillespie, D. A. F., Jackson, D. A., & Caldecott, K. W. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.3319-3326.2006 · Cited by 181
Bahassi, E. M., Ovesen, J. L., Riesenberg, A. L., Bernstein, W. Z., Hasty, P. E., & Stambrook, P. J. (2008) · Oncogene · doi:10.1038/onc.2008.17 · Cited by 180
Dai, Y., Yu, C., Singh, V., Tang, L., Wang, Z., McInistry, R., Dent, P., & Grant, S. (2001) · PubMed · Cited by 176
Jossé, R., Martin, S. E., Guha, R., Ormanoglu, P., Pfister, T. D., Reaper, P. M., Barnes, C. S., Jones, J., Charlton, P., Pollard, J. R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3369 · Cited by 172
Guzi, T. J., Paruch, K., Dwyer, M. P., Labroli, M., Shanahan, F., Davis, N., Taricani, L., Wiswell, D., Seghezzi, W., Penaflor, E., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0928 · Cited by 171
Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
Pires, I. M., Olcina, M. M., Anbalagan, S., Pollard, J. R., Reaper, P. M., Charlton, P. A., McKenna, W. G., & Hammond, E. M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.265 · Cited by 170
Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment
Scanlon, S. E., & Glazer, P. M. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.04.030 · Cited by 165
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
Hong, D., Infante, J., Janku, F., Jones, S., Nguyen, L. M., Burris, H. A., Naing, A., Bauer, T. M., Piha-Paul, S., Johnson, F. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.5788 · Cited by 159
Replication fork dynamics and the DNA damage response
Jones, R. M., & Petermann, E. (2012) · Biochemical Journal · doi:10.1042/bj20112100 · Cited by 157
Matthews, D. J., Yakes, M., Chen, J., Tadano, M., Bornheim, L. M., Clary, D. O., Tai, A., Wagner, J. M., Miller, N., Kim, Y. D., et al. (2007) · Cell Cycle · doi:10.4161/cc.6.1.3699 · Cited by 153
Tse, A. N., Rendahl, K. G., Sheikh, T. N., Cheema, H., Aardalen, K., Embry, M. G., Ma, S., Moler, E. J., Ni, Z., de Menezes, D. E. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1424 · Cited by 153
Parsels, L. A., Morgan, M. A., Tanska, D. M., Parsels, J. D., Palmer, B. D., Booth, R. J., Denny, W. A., Canman, C. E., Kraker, A. J., Lawrence, T. S., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0662 · Cited by 153
Chk1-Mediated Phosphorylation of FANCE Is Required for the Fanconi Anemia/BRCA Pathway
Wang, X., Kennedy, R. D., Ray, K., Stuckert, P., Ellenberger, T., & D’Andrea, A. D. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02357-06 · Cited by 152
ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency
Mohni, K. N., Kavanaugh, G. M., & Cortez, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3229 · Cited by 150
Mitchell, J. B., Choudhuri, R., Fabre, K. M., Sowers, A. L., Citrin, D. E., Zabludoff, S., & Cook, J. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3277 · Cited by 149
Verlinden, L., Bempt, I. V., Eelen, G., Drijkoningen, M., Verlinden, I., Marchal, K., Wolf‐Peeters, C. D., Christiaens, M.-R., Michiels, L., Bouillon, R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3545 · Cited by 149
Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
Sanjiv, K., Hagenkort, A., Calderón‐Montaño, J. M., Koolmeister, T., Reaper, P. M., Mortusewicz, O., Jacques, S. A., Kuiper, R., Schultz, N., Scobie, M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.12.032 · Cited by 149
Targeting Checkpoint Kinase 1 in Cancer Therapeutics
Tse, A. N., Carvajal, R. D., & Schwartz, G. K. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2793 · Cited by 148
Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival
Karnitz, L. M., Flatten, K. S., Wagner, J. M., Loegering, D. A., Hackbarth, J. S., Arlander, S. J. H., Vroman, B. T., Thomas, M. B., Baek, Y.-U., Hopkins, K. M., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.012716 · Cited by 148
Replication stress and cancer: It takes two to tango
Lecona, E., & Fernández-Capetillo, Ó. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.09.019 · Cited by 147
Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response
Nishida, H., Tatewaki, N., Nakajima, Y., Magara, T., Ko, K. M., Hamamori, Y., & Konishi, T. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp593 · Cited by 147
Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells
Höglund, A., Nilsson, L. M., Muralidharan, S. V., Hasvold, L. A., Merta, P. J., Rudelius, M., Nikolova, V. D., Keller, U. B., & Nilsson, J. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1198 · Cited by 146
Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei
Dillon, M. T., Barker, H. E., Pedersen, M., Hafsi, H., Bhide, S. A., Newbold, K. L., Nutting, C. M., McLaughlin, M., & Harrington, K. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0239 · Cited by 140
Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells
Ferrao, P. T., Bukczynska, E. P., Johnstone, R. W., & McArthur, G. A. (2012) · Oncogene · doi:10.1038/onc.2011.358 · Cited by 133
Targeting DNA repair, DNA metabolism and replication stress as anti‐cancer strategies
Puigvert, J. C., Sanjiv, K., & Helleday, T. (2015) · FEBS Journal · doi:10.1111/febs.13574 · Cited by 132
An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation
Lopez-Contreras, A. J., Gutierrez‐Martinez, P., Specks, J., Rodrigo-Perez, S., & Fernández-Capetillo, Ó. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20112147 · Cited by 132
Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma
Russell, M. R., Levin, K., Rader, J., Belcastro, L. T., Li, Y., Martínez, D., Pawel, B., Shumway, S. D., Maris, J. M., & Cole, K. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2669 · Cited by 130
Wang, H., Wang, H., Powell, S. N., Iliakis, G., & Wang, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1289 · Cited by 130
CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors
Chen, C. C., Kennedy, R. D., Sidi, S., Look, A. T., & D’Andrea, A. D. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-24 · Cited by 129
Gadhikar, M. A., Sciuto, M. R., Alves, M. V. O., Pickering, C. R., Osman, A. A., Neskey, D. M., Zhao, M., Fitzgerald, A. L., Myers, J. N., & Frederick, M. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0157 · Cited by 129
Thompson, R. H., & Eastman, A. R. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12139 · Cited by 128
Montano, R. E., Chung, I., Garner, K. M., Parry, D., & Eastman, A. R. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0406 · Cited by 128
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma
Hong, J., Hu, K., Yuan, Y., Sang, Y., Bu, Q., Chen, G., Yang, L., Li, B., Huang, P., Chen, D., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61380 · Cited by 127
Bryant, C., Rawlinson, R., & Massey, A. J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-570 · Cited by 125
Karp, J. E., Thomas, B. M., Greer, J. M., Sorge, C. L., Gore, S. D., Pratz, K. W., Smith, B. D., Flatten, K. S., Peterson, K., Schneider, P. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2442 · Cited by 123
Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication
Foskolou, I. P., Jorgensen, C., Leszczyńska, K. B., Olcina, M. M., Tarhonskaya, H., Haisma, B., D’Angiolella, V., Myers, W. K., Domene, C., Flashman, E., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.03.005 · Cited by 122
Targeting Hypoxic Cells through the DNA Damage Response
Olcina, M. M., Lecane, P. S., & Hammond, E. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0286 · Cited by 119
Azorsa, D. O., Gonzales, I. M., Basu, G. D., Choudhary, A. K., Arora, S., Bisanz, K. M., Kiefer, J., Henderson, M. C., Trent, J. M., Hoff, D. D. V., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-43 · Cited by 115
Inhibition of ATR Leads to Increased Sensitivity to Hypoxia/Reoxygenation
Hammond, E. M., Dorie, M. J., & Giaccia, A. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1520 · Cited by 115
Carrassa, L., Chilà, R., Lupi, M., Ricci, F., Celenza, C., Mazzoletti, M., Broggini, M., & Damia, G. L. M. (2012) · Cell Cycle · doi:10.4161/cc.20899 · Cited by 113
Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor
King, C., Diaz, H., Barnard, D., Barda, D. A., Clawson, D. K., Blosser, W. D., Cox, K. L., Guo, S., & Marshall, M. S. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0036-7 · Cited by 110
The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106
Walton, M. I., Eve, P. D., Hayes, A., Valenti, M. R., Brandon, A. D. H., Box, G., Boxall, K. J., Aherne, G. W., Eccles, S. A., Raynaud, F. I., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0938 · Cited by 110
Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776
Engelke, C. G., Parsels, L. A., Qian, Y., Zhang, Q., Karnak, D. M., Robertson, J. R., Tanska, D. M., Wei, D., Davis, M. A., Parsels, J. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3748 · Cited by 109
Menezes, D. L. D., Holt, J., Tang, Y., Feng, J., Barsanti, P. A., Pan, Y., Ghoddusi, M., Zhang, W., Thomas, G., Holash, J. A., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0240 · Cited by 109
Mohni, K. N., Thompson, P. S., Luzwick, J. W., Glick, G. G., Pendleton, C. S., Lehmann, B. D., Pietenpol, J. A., & Cortez, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125482 · Cited by 108
A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress
Brooks, K. M., Oakes, V., Edwards, B., Ranall, M. V., Leo, P., Pavey, S. J., Pinder, A., Beamish, H., Mukhopadhyay, P., Lambie, D., et al. (2012) · Oncogene · doi:10.1038/onc.2012.72 · Cited by 107
Kohn, E. A., Ruth, N. D., Brown, M. K., Livingstone, M., & Eastman, A. R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202040200 · Cited by 106
Dai, Y., Chen, S., Pei, X., Almenara, J. A., Kramer, L. B., Venditti, C. A., Dent, P., & Grant, S. (2008) · Blood · doi:10.1182/blood-2008-05-159392 · Cited by 105
The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons
Flatten, K. S., Dai, N. T., Vroman, B. T., Loegering, D. A., Erlichman, C., Karnitz, L. M., & Kaufmann, S. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411890200 · Cited by 104
Seto, T., Esaki, T., Hirai, F., Arita, S., Nosaki, K., Makiyama, A., Kometani, T., Fujimoto, C., Hamatake, M., Takeoka, H., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2234-6 · Cited by 104
Tse, A. N., & Schwartz, G. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0841 · Cited by 102
Jobson, A. G., Lountos, G. T., Lorenzi, P. L., Llamas, J., Connelly, J., Cerna, D., Tropea, J. E., Onda, A., Zoppoli, G. M., Kondapaka, S. B., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.154997 · Cited by 100
McNeely, S., Conti, C., Sheikh, T. N., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.5.10935 · Cited by 98
CHK1 Inhibitors in Combination Chemotherapy: Thinking Beyond the Cell Cycle
Dent, P., Tang, Y., Yacoub, A., Dai, Y., Fisher, P. B., & Grant, S. (2011) · Molecular Interventions · doi:10.1124/mi.11.2.11 · Cited by 97
Claspin and Chk1 regulate replication fork stability by different mechanisms
Scorah, J., & McGowan, C. H. (2009) · Cell Cycle · doi:10.4161/cc.8.7.8040 · Cited by 97
Ruzankina, Y., Schoppy, D. W., Asare, A., Clark, C. E., Vonderheide, R. H., & Brown, E. J. (2009) · Nature Genetics · doi:10.1038/ng.441 · Cited by 97
Assessment of Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition
Parsels, L. A., Qian, Y., Tanska, D. M., Gross, M., Zhao, L., Hassan, M. C., Arumugarajah, S., Parsels, J. D., Hylander-Gans, L., Simeone, D. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3082 · Cited by 97
Vance, S. M., Pollom, E. L., Zhao, L., Parsels, J. D., Parsels, L. A., Brown, J. L., Maybaum, J., Lawrence, T. S., & Morgan, M. A. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18661 · Cited by 96
ATR inhibition preferentially targets homologous recombination-deficient tumor cells
Krajewska, M., Fehrmann, R. S. N., Schoonen, P. M., Labib, S., de Vries, E. G. E., Franke, L., & van Vugt, M. A. T. M. (2014) · Oncogene · doi:10.1038/onc.2014.276 · Cited by 94
Walton, M. I., Eve, P. D., Hayes, A., Valenti, M. R., Brandon, A. K. D. H., Box, G., Hallsworth, A., Smith, E. L., Boxall, K. J., Lainchbury, M. D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1322 · Cited by 94
Luciani, M. G., Oehlmann, M., & Blow, J. J. (2004) · Journal of Cell Science · doi:10.1242/jcs.01400 · Cited by 94
Comparison of hypoxia-induced replication arrest with hydroxyurea and aphidicolin-induced arrest
Hammond, E. M., Green, S., & Giaccia, A. J. (2003) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2003.08.017 · Cited by 91
Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation
Davies, K. D., Cable, P. L., Garrus, J. E., Sullivan, F. X., von Carlowitz, I., Huérou, Y. L., Wallace, E. M., Woessner, R. D., & Gross, S. D. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.9.17673 · Cited by 89
Sultana, R., Abdel-Fatah, T. M. A., Perry, C., Moseley, P. M., Albarakati, N., mohan, V. C., Seedhouse, C., Chan, S. Y. T., & Madhusudan, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057098 · Cited by 87
Cavelier, C., Didier, C., Prade, N., Mas, V. M., Manenti, S., Récher, C., Demur, C., & Ducommun, B. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0939 · Cited by 87
Guertin, A. D., Martin, M. M., Roberts, B. S., Hurd, M. S., Qu, X., Miselis, N. R., Liu, Y., Li, J., Feldman, I., Benita, Y., et al. (2012) · Cancer Cell International · doi:10.1186/1475-2867-12-45 · Cited by 87
Li, L., Chang, W., Yang, G., Ren, C., Park, S., Karantanos, T., Karanika, S., Wang, J., Yin, J., Shah, P. K., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005070 · Cited by 84
Development of Synthetic Lethality Anticancer Therapeutics
Fang, B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500415t · Cited by 81
Montano, R. E., Thompson, R. H., Chung, I., Hou, H. G., Khan, N. I., & Eastman, A. R. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-604 · Cited by 77
Sarmento, L. M., Póvoa, V., Nascimento, R., Real, G., Antunes, I., Martins, L. R., Moita, C. F., Alves, P. M., Abecasis, M., Moita, L. F., et al. (2014) · Oncogene · doi:10.1038/onc.2014.248 · Cited by 75
Dai, Y., Khanna, P., Chen, S., Pei, X., Dent, P., & Grant, S. (2007) · Blood · doi:10.1182/blood-2006-09-047076 · Cited by 74
Oza, V. B., Ashwell, S., Almeida, L., Brassil, P. J., Breed, J., Deng, C., Gero, T. W., Grondine, M. R., Horn, C. L., Ioannidis, S., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300025r · Cited by 74
Cázares-Körner, C., Pires, I. M., Swallow, I. D., Grayer, S. C., O’Connor, L. J., Olcina, M. M., Christlieb, M., Conway, S. J., & Hammond, E. M. (2013) · ACS Chemical Biology · doi:10.1021/cb4001537 · Cited by 73
Boyer, A.-S., Walter, D., & Sørensen, C. S. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.01.001 · Cited by 72
Tao, Y., Leteur, C., Yang, C., Ping, Z., Castedo, M., Pierré, A., Golsteyn, R. M., Bourhis, J., Kroemer, G., & Deutsch, É. (2009) · Cell Cycle · doi:10.4161/cc.8.8.8203 · Cited by 71
Scagliotti, G., Kang, J. H., Smith, D. C., Rosenberg, R. K., Park, K., Kim, S.-W., Su, W., Boyd, T. E., Richards, D., Novello, S., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0368-1 · Cited by 70
Cross-talk between Chk1 and Chk2 in double-mutant thymocytes
Zaugg, K., Su, Y., Reilly, P. T., Moolani, Y., Cheung, C. C., Hakem, R., Hirao, A., Liu, Q., Elledge, S. J., & Mak, T. W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611584104 · Cited by 69
Ma, Z., Yao, G., Zhou, B. O., Fan, Y., Gao, S., & Feng, X. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.999 · Cited by 68
Dees, E. C., Baker, S. D., O’Reilly, S., Rudek, M. A., Davidson, S. B., Aylesworth, C. A., Elza-Brown, K., Carducci, M. A., & Donehower, R. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.664.11.2 · Cited by 68
CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus
Koh, S., Courtin, A., Boyce, R. J., Boyle, R. G., Richards, F. M., & Jodrell, D. I. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3347 · Cited by 68
Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing
Reader, J. C., Matthews, T. P., Klair, S., Cheung, K.-M. J., Scanlon, J., Proisy, N., Addison, G., Ellard, J. M., Piton, N., Taylor, S., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007326 · Cited by 64
Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
Chilà, R., Basana, A., Lupi, M., Guffanti, F., Gaudio, E., Rinaldi, A., Cascione, L., Restelli, V., Tarantelli, C., Bertoni, F., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2583 · Cited by 63
Calvo, E., Chen, V. J., Marshall, M. S., Ohnmacht, U., Hynes, S. M., Kumm, E., Diaz, H. B., Barnard, D., Merzoug, F. F., Huber, L., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0114-5 · Cited by 63
Zhang, C., Yan, Z., Painter, C. L., Zhang, Q., Chen, E., Arango, M. E., Kuszpit, K. K., Zasadny, K. R., Hallin, M. E., Hallin, J. F., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3272 · Cited by 63
PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells
Booth, L. A., Cruickshanks, N. A., Ridder, T. S., Dai, Y., Grant, S., & Dent, P. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.24424 · Cited by 62
Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor
Xiao, Y., Ramiscal, J. A. B., Kowanetz, K., Nagro, C. J. D., Malek, S., Evangelista, M., Blackwood, E. R., Jackson, P. K., & O’Brien, T. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0404 · Cited by 62
Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors
Lee, J., Choy, M. L., Ngo, L., Venta-Perez, G., & Marks, P. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117544108 · Cited by 59
Targeted Radiosensitization by the Chk1 Inhibitor SAR-020106
Borst, G. R., McLaughlin, M., Kyula, J., Neijenhuis, S., Khan, A., Good, J. S., Zaidi, S., Powell, N. G., Meier, P., Collins, I., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.08.006 · Cited by 59
Weiss, G. J., Donehower, R. C., Iyengar, T., Ramanathan, R. K., Lewandowski, K., Westin, E. H., Hurt, K. C., Hynes, S. M., Anthony, S. P., & McKane, S. W. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9815-9 · Cited by 59
Schenk, E. L., Koh, B. D., Flatten, K. S., Peterson, K. L., Parry, D., Hess, A. D., Smith, B. D., Karp, J. E., Karnitz, L. M., & Kaufmann, S. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0961 · Cited by 59
Zhi, G., Wilson, J. B., Chen, X., Krause, D. S., Xiao, Y., Jones, N. J., & Kupfer, G. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2312 · Cited by 58
Li, T., Christensen, S., Frankel, P. H., Margolin, K. A., Agarwala, S. S., Luu, T. H., Mack, P. C., Lara, P. N., & Gandara, D. R. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9562-8 · Cited by 58
Zenvirt, S., Kravchenko‐Balasha, N., & Levitzki, A. (2010) · Oncogene · doi:10.1038/onc.2010.343 · Cited by 57
Carrassa, L., Broggini, M., Vikhanskaya, F., & Damia, G. L. M. (2003) · Cell Cycle · doi:10.4161/cc.2.6.503 · Cited by 57
Landau, H. J., McNeely, S., Nair, J. S., Comenzo, R. L., Asai, T., Friedman, H., Jhanwar, S. C., Nimer, S. D., & Schwartz, G. K. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0949 · Cited by 57
Feng, Z., & Zhang, J. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr748 · Cited by 56
Self-citationSha, S.-K., Sato, T., Kobayashi, H., Ishigaki, M., Yamamoto, S., Sato, H., Takada, A., Nakajyo, S., Mochizuki, Y., Friedman, J. M., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0371 · Cited by 51
Grabauskiene, S., Bergeron, E. J., Chen, G., Chang, A. C., Lin, J., Thomas, D. G., Giordano, T. J., Beer, D. G., Morgan, M. A., & Reddy, R. M. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.09.010 · Cited by 50
Magnussen, G. I., Emilsen, E., Fleten, K. G., Engesæter, B. Ø., Nähse, V., Fjær, R., Slipicevic, A., & Flørenes, V. A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1474-8 · Cited by 50
CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy
Barker, H. E., Patel, R., McLaughlin, M., Schick, U., Zaidi, S., Nutting, C. M., Newbold, K. L., Bhide, S. A., & Harrington, K. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0998 · Cited by 49
Fujisawa, H., Nakajima, N. I., Sunada, S., Lee, Y., Hirakawa, H., Yajima, H., Fujimori, A., Uesaka, M., & Okayasu, R. (2015) · Radiation Oncology · doi:10.1186/s13014-015-0464-y · Cited by 48
Leszczyńska, K. B., Dobrynin, G., Leslie, R. E., Ient, J., Boumelha, A. J., Senra, J. M., Hawkins, M., Maughan, T., Mukherjee, S., & Hammond, E. M. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.10.023 · Cited by 48
Pei, X., Dai, Y., Youssefian, L. E., Chen, S., Bodie, W. W., Takabatake, Y., Felthousen, J. G., Almenara, J. A., Kramer, L. B., Dent, P., et al. (2011) · Blood · doi:10.1182/blood-2011-02-339432 · Cited by 47
Liu, Y., Vidanes, G. M., Lin, Y.-T., Mori, S., & Siede, W. (2000) · Molecular and General Genetics MGG · doi:10.1007/pl00008656 · Cited by 47
Enhancing CHK1 inhibitor lethality in glioblastoma
Tang, Y., Dai, Y., Grant, S., & Dent, P. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.19240 · Cited by 46
Identification of novel,in vivoactive Chk1 inhibitors utilizing structure guided drug design
Massey, A. J., Stokes, S. P., Browne, H. L., Foloppe, N., Fiumana, A., Scrace, S., Fallowfield, M., Bedford, S. T., Webb, P., Baker, L. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5929 · Cited by 46
Pei, X., Dai, Y., Tenorio, S., Lu, J., Harada, H., Dent, P., & Grant, S. (2007) · Blood · doi:10.1182/blood-2007-04-083204 · Cited by 44
Wang, G. T., Li, G., Mantei, R. A., Chen, Z., Kovar, P. J., Gu, W., Xiao, Z., Zhang, H., Sham, H. L., Sowin, T. J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm048989d · Cited by 43
Busch, C., Kriegs, M., Laban, S. A., Tribius, S., Knecht, R., Petersen, C., Dikomey, E., & Rieckmann, T. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.06.035 · Cited by 42
Hocke, S., Guo, Y., Job, A., Orth, M., Ziesch, A., Lauber, K., Toni, E. N. D., Gress, T. M., Herbst, A., Göke, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6857 · Cited by 42
ATR inhibition rewires cellular signaling networks induced by replication stress
Wagner, S., Oehler, H., Voigt, A., Dalic, D., Freiwald, A., Serve, H. L., & Beli, P. (2015) · PROTEOMICS · doi:10.1002/pmic.201500172 · Cited by 41
Lee, S. I., Brown, M. K., & Eastman, A. R. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00258-0 · Cited by 40
Vávrová, J., Zárybnická, L., Lukášová, E., Řezáčová, M., Novotná, E., Šinkorová, Z., Tichý, A., Pejchal, J., & Ďurišová, K. (2013) · Radiation and Environmental Biophysics · doi:10.1007/s00411-013-0486-5 · Cited by 40
Zhang, Y., Lai, J., Du, Z., Gao, J., Yang, S., Gorityala, S., Xiong, X., Deng, O., Ma, Z., Yan, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9156 · Cited by 40
Self-citationAl‐Ejeh, F., Pajic, M., Shi, W., Kalimutho, M., Miranda, M. S., Nagrial, A. M., Chou, A. S. Y., Biankin, A. V., Grimmond, S. M., Initiative, F. T. A. P. C. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0048 · Cited by 39
Robles, A. I., Wright, M. H., Gandhi, B., Feis, S. S., Hanigan, C. L., Wiestner, A. U., & Varticovski, L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1178 · Cited by 39
MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells
Bridges, K. A., Chen, X., Liu, H., Rock, C. D., Buchholz, T. A., Shumway, S. D., Skinner, H. D., & Meyn, R. E. (2016) · Oncotarget · doi:10.18632/oncotarget.12311 · Cited by 39
Doi, T., Yoshino, T., Shitara, K., Matsubara, N., Fuse, N., Naito, Y., Uenaka, K., Nakamura, T., Hynes, S. M., & Bence, A. K. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000278 · Cited by 37
Poly(ADP-ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Mammary Tumors
Tang, Y., Hamed, H. A., Poklepovic, A. S., Dai, Y., Grant, S., & Dent, P. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.078907 · Cited by 37
Suzuki, M., Yamamori, T., Bo, T., Sakai, Y., & Inanami, O. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.04.002 · Cited by 37
Mak, J. P. Y., Man, W. Y., Ma, H. T., & Poon, R. Y. C. (2014) · Oncotarget · doi:10.18632/oncotarget.2508 · Cited by 33
Lainchbury, M. D., Matthews, T. P., McHardy, T., Boxall, K. J., Walton, M. I., Eve, P. D., Hayes, A., Valenti, M. R., Brandon, A. K. D. H., Box, G., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3012933 · Cited by 32
Shapiro, G. I., Tibes, R., Gordon, M. S., Wong, B. Y., Eder, J. P., Borad, M. J., Mendelson, D. S., Vogelzang, N. J., Bastos, B. R., Weiss, G. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2345 · Cited by 31
Krug, L. M., Woźniak, A., Kindler, H. L., Feld, R. D., Koczywas, M., Morero, J. L., Rodriguez, C. P., Ross, H. J., Bauman, J. E., Орлов, С. В., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.06.008 · Cited by 31
Preet, R., Siddharth, S., Satapathy, S. R., Das, S., Nayak, A., Das, D., Wyatt, M. D., & Kundu, C. N. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.01.017 · Cited by 31
Development of pharmacodynamic biomarkers for ATR inhibitors
Chen, T., Middleton, F. K., Falcon, S. C., Reaper, P. M., Pollard, J. R., & Curtin, N. J. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.09.012 · Cited by 30
Cited by
Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Pan, L., Feng, F., Wu, J., Fan, S., Han, J., Wang, S., Yang, L., Liu, W., Wang, C., & Xu, K. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106270 · Cited by 383
Gain-of-function mutant p53 in cancer progression and therapy
Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 334
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
Ghelli Luserna di Rorà, A., Cerchione, C., Martinelli, G., & Simonetti, G. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00959-2 · Cited by 314
Metadata
- Authors
- Qiu, Z., Oleinick, N. L., & Zhang, J.
- Venue
- Radiotherapy and Oncology
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 126
- Issue
- 3
- Pages
- 450-464
- ISSN
- 0167-8140 (ISSN-L)
- OpenAlex
- W2766300480
- Cited by
- 370
- References
- 210
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.